AUB ScholarWorks

Management of Relapses After Hematopoietic Cell Transplantation in T-Cell Non-Hodgkin Lymphomas

Show simple item record Hamadani M. Abu Kar S.M. Usmani S.Z. Savani B.N. Ayala E. Kharfan-Dabaja M.A.
dc.contributor.editor 2014 2017-10-05T15:42:09Z 2017-10-05T15:42:09Z 2014
dc.identifier 10.1053/j.seminhematol.2013.11.005
dc.identifier.issn 00371963
dc.description.abstract T-cell non-Hodgkin lymphomas (NHLs) are a heterogeneous group of malignancies that represent 10percent-15percent of all NHLs. The prognosis of relapsed T-cell NHL is poor, especially for those relapsing after an autologous (auto-) or allogeneic (allo-) hematopoietic cell transplantation (HCT). Disease relapse post auto-HCT is best managed on a clinical trial. In the absence of an investigational protocol, the choice of salvage therapies should take into account patient performance status, eligibility for an allo-HCT, and surface CD30 expression. CD30-directed therapies or aggressive salvage regimens can be used as a bridge to allo-HCT in medically fit patients. In the elderly or more infirm patients, single-agent therapies could be offered, aiming at palliation. Similarly, relapse after an allo-HCT is not uncommon and is a real challenge. Reduction in ongoing immune suppression or donor lymphocyte infusion are often considered in this setting to augment graft-versus-lymphoma (GVL) effects and can occasionally provide durable disease control. Clinical trials designed to investigate novel therapeutic agents with immunomodulatory properties to augment GVL effects (eg, histone deacetylase [HDAC] inhibitors, proteasome inhibitor, lenalidomide) or targeted therapies (eg, aurora A kinase inhibitors, anaplastic lymphoma kinase [ALK] inhibitors) are sorely needed to improve the dismal outcomes of T-cell NHL relapsing after an allo-HCT. © 2014 Elsevier Inc.
dc.format.extent Pages: (73-86)
dc.language English
dc.publisher PHILADELPHIA
dc.relation.ispartof Publication Name: Seminars in Hematology; Publication Year: 2014; Volume: 51; no. 1; Pages: (73-86);
dc.source Scopus
dc.title Management of Relapses After Hematopoietic Cell Transplantation in T-Cell Non-Hodgkin Lymphomas
dc.type Article
dc.contributor.affiliation Hamadani, M., Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, United States
dc.contributor.affiliation Abu Kar, S.M., Division of Hematology-Oncology, American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Usmani, S.Z., Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, United States
dc.contributor.affiliation Savani, B.N., Hematology and Stem Cell Transplantation Section, Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
dc.contributor.affiliation Ayala, E., Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Inst., Univ. of South Florida College of Medicine, Tampa, FL, United States
dc.contributor.affiliation Kharfan-Dabaja, M.A., Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Inst., Univ. of South Florida College of Medicine, Tampa, FL, United States
dc.contributor.authorAddress Hamadani, M.; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, United States; email:
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; Division: Hematology-Oncology;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision Hematology-Oncology
dc.contributor.faculty Faculty of Medicine
dc.contributor.authorInitials Hamadani, M
dc.contributor.authorInitials Abu Kar, SM
dc.contributor.authorInitials Usmani, SZ
dc.contributor.authorInitials Savani, BN
dc.contributor.authorInitials Ayala, E
dc.contributor.authorInitials Kharfan-Dabaja, MA
dc.contributor.authorReprintAddress Hamadani, M (reprint author), Med Coll Wisconsin, Div Hematol and Oncol, Milwaukee, WI 53226 USA.
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Advani RH, 2012, LEUKEMIA LYMPHOMA, V53, P718, DOI 10.3109-10428194.2011.623256; Arkenau HT, 2007, HAEMATOL-HEMATOL J, V92, P271, DOI 10.3324-haematol.10737; Blum KA, 2010, ANN ONCOL, V21, P2246, DOI 10.1093-annonc-mdq211; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038-nrd2133; Chang ST, 2007, LEUKEMIA LYMPHOMA, V48, P117, DOI 10.1080-10428190601016167; Chen R, 2012, BLOOD, V119, P6379, DOI 10.1182-blood-2012-03-418673; Coiffier B, 2012, J CLIN ONCOL, V30, P631, DOI 10.1200-JCO.2011.37.4223; Coman T, 2013, HAEMATOLOGICA, V98, P776, DOI 10.3324-haematol.2012.069328; Corradini P, 2004, J CLIN ONCOL, V22, P2172, DOI 10.1200-JCO.2004.12.050; Damaj G, 2013, J CLIN ONCOL, V31, P104, DOI 10.1200-JCO.2012.43.7285; d'Amore F, 2010, BRIT J HAEMATOL, V150, P565, DOI 10.1111-j.1365-2141.2010.08298.x; d'Amore F, 2012, J CLIN ONCOL, V30, P3093, DOI 10.1200-JCO.2011.40.2719; Dang NH, 2007, BRIT J HAEMATOL, V136, P439, DOI 10.1111-j.1365-2141.2006.06457.x; Dodero A, 2012, LEUKEMIA, V26, P520, DOI 10.1038-leu.2011.240; Dueck G, 2010, CANCER-AM CANCER SOC, V116, P4541, DOI 10.1002-cncr.25377; Enblad G, 2004, BLOOD, V103, P2920, DOI 10.1182-blood-2003-10-3389; Evens A, 2011, ASH ANN M, V118, P1646; Foss FM, 2011, BLOOD, V117, P6756, DOI 10.1182-blood-2010-05-231548; Friedberg J, 2011, ASH ANN M ABSTR, V118, P95; Gambacorti-Passerini C, 2011, NEW ENGL J MED, V364, P775, DOI 10.1056-NEJMc1013224; Gibb A, 2013, HAEMATOLOGICA, V98, P611, DOI 10.3324-haematol.2012.069393; Goldenberg Marvin M, 2008, P T, V33, P299; Hamadani M, 2008, BIOL BLOOD MARROW TR, V14, P480, DOI [10.1016-j.bbmt.2008.01.002, 10.1016-j.bbnit.2008.01.002]; Horwitz SM, 2012, BLOOD, V119, P4115, DOI 10.1182-blood-2011-11-390211; Iqbal J, 2011, LEUKEMIA, V25, P348, DOI 10.1038-leu.2010.255; Ishida T, 2012, BLOOD, V120, P1734, DOI 10.1182-blood-2012-03-414490; Ishida T, 2012, J CLIN ONCOL, V30, P837, DOI 10.1200-JCO.2011.37.3472; Itonaga H, 2013, BLOOD, V121, P219, DOI 10.1182-blood-2012-07-444372; Iwata S, 2011, INT J CANCER, V129, P2263, DOI 10.1002-ijc.25873; Kanakry JA, 2013, BIOL BLOOD MARROW TR, V19, P602, DOI 10.1016-j.bbmt.2013.01.006; Kim SJ, 2012, INVEST NEW DRUG, V30, P368, DOI 10.1007-s10637-010-9523-2; Kim SW, 2006, BLOOD, V108, P382, DOI 10.1182-blood-2005-02-0596; Kneppers E, 2011, BLOOD, V118, P2413, DOI 10.1182-blood-2011-04-348292; KOLB HJ, 1990, BLOOD, V76, P2462; Koreth J, 2012, J CLIN ONCOL, V30, P3202, DOI 10.1200-JCO.2012.42.0984; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056-NEJMoa1006448; Kyriakou C, 2009, J CLIN ONCOL, V27, P3951, DOI 10.1200-JCO.2008.20.4628; Lee J, 2008, ANN ONCOL, V19, P2079, DOI 10.1093-annonc-mdn431; Le Gouill S, 2008, J CLIN ONCOL, V26, P2264, DOI 10.1200-JCO.2007.14.1366; Leng C, 2006, EXP HEMATOL, V34, P776, DOI 10.1016-j.exphem.2006.02.014; Mak V, 2013, J CLIN ONCOL, V31, P1970, DOI 10.1200-JCO.2012.44.7524; McIver ZA, 2013, BONE MARROW TRANSPL, V48, P1192, DOI 10.1038-bmt.2013.39; Mercadal S, 2008, ANN ONCOL, V19, P958, DOI 10.1093-annonc-mdn022; Mikesch JH, 2013, ANN HEMATOL, V92, P1041, DOI 10.1007-s00277-013-1738-9; Nademanee A, 2011, BIOL BLOOD MARROW TR, V17, P1481, DOI 10.1016-j.bbmt.2011.02.008; O'Mahony D, 2005, ASH ANN M ABSTR, V106, P3353; O'Connor OA, 2011, J CLIN ONCOL, V29, P1182, DOI 10.1200-JCO.2010.29.9024; Ordemann R, 2013, ANN HEMATOL, V92, P125, DOI 10.1007-s00277-012-1524-0; Orlowski RZ, 2007, J CLIN ONCOL, V25, P3892, DOI 10.1200-JCO.2006.10.5460; Pattison NA, 2011, J RELIG HEALTH, V50, P731, DOI 10.1007-s10943-009-9265-7; Pettengell R, 2012, LANCET ONCOL, V13, P696, DOI 10.1016-S1470-2045(12)70212-7; Piccaluga PP, 2007, HAEMATOL-HEMATOL J, V92, P566, DOI 10.3324-haematol.10767; Piekarz RL, 2011, BLOOD, V117, P5827, DOI 10.1182-blood-2010-10-312603; Pohlman B, 2009, ASH ANN M, V114, P920; Pro B, 2012, J CLIN ONCOL, V30, P2190, DOI 10.1200-JCO.2011.38.0402; Puig N, 2013, LEUKEMIA LYMPHOMA, V54, P507, DOI 10.3109-10428194.2012.719615; Qi WQ, 2013, LEUKEMIA RES, V37, P434, DOI 10.1016-j.leukres.2012.10.017; Querfeld C, 2011, LEUKEMIA LYMPHOMA, V52, P1474, DOI 10.3109-10428194.2011.572265; Rasheed W, 2008, EXPERT REV ANTICANC, V8, P413, DOI 10.1586-14737140.8.3.413; Reddy P, 2008, J CLIN INVEST, V118, P2562, DOI 10.1172-JCI34712; Reimer P, 2009, J CLIN ONCOL, V27, P106, DOI 10.1200-JCO.2008.17.4870; Rodriguez J, 2007, HAEMATOL-HEMATOL J, V92, P1067, DOI 10.3324-haematol.11173; Savage KJ, 2011, HEMATOL-AM SOC HEMAT, P515, DOI 10.1182-asheducation-2011.1.515; Savage KJ, 2008, BLOOD, V111, P5496, DOI 10.1182-blood-2008-01-134270; SHIPP MA, 1995, J CLIN ONCOL, V13, P2916; Sibon D, 2012, J CLIN ONCOL, V30, P3939, DOI 10.1200-JCO.2012.42.2345; Singh R, 2012, CLIN CANCER RES, V18, P152, DOI 10.1158-1078-0432.CCR-11-1839; Sockel K, 2012, HAEMATOL-HEMATOL J, V97, pE34, DOI 10.3324-haematol.2012.067629; Sung W, 2013, BIOL BLOOD MARROW TR, V19, pS109; Tan D, 2012, ASH ANN M, V120, P3669; Tomblyn M, 2008, BONE MARROW TRANSPL, V42, P569, DOI 10.1038-bmt.2008.259; Uike N, 2012, ASH ANN M, V120, P2737; Vose JM, 2008, J CLIN ONCOL, V26, P4124, DOI 10.1200-JCO.2008.16.4558; Weidmann E, 2010, LEUKEMIA LYMPHOMA, V51, P447, DOI 10.3109-10428190903580402; Yang DH, 2009, BIOL BLOOD MARROW TR, V15, P118, DOI 10.1016-j.bbmt.2008.11.010; Yao YY, 2013, LEUKEMIA LYMPHOMA, V54, P1194, DOI 10.3109-10428194.2012.739286; Younes A, 2010, NEW ENGL J MED, V363, P1812, DOI 10.1056-NEJMoa1002965; Zhao WL, 2008, BLOOD, V111, P3867, DOI 10.1182-blood-2007-08-108654; Zinzani PL, 2010, ANN ONCOL, V21, P860, DOI 10.1093-annonc-mdp508
dc.description.citedCount 1
dc.description.citedTotWOSCount 2
dc.description.citedWOSCount 2
dc.format.extentCount 14
dc.identifier.coden SEHEA
dc.identifier.pubmedID 24468319
dc.identifier.scopusID 84892844240
dc.publisher.address 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
dc.relation.ispartOfISOAbbr Semin. Hematol.
dc.relation.ispartOfIssue 1
dc.relation.ispartofPubTitle Seminars in Hematology
dc.relation.ispartofPubTitleAbbr Semin. Hematol.
dc.relation.ispartOfVolume 51
dc.source.ID WOS:000330602900010
dc.type.publication Journal
dc.subject.otherChemCAS alemtuzumab, 216503-57-0
dc.subject.otherChemCAS alisertib, 1028486-01-2, 1208255-63-3
dc.subject.otherChemCAS bendamustine, 16506-27-7, 3543-75-7
dc.subject.otherChemCAS brentuximab vedotin, 914088-09-8
dc.subject.otherChemCAS carboplatin, 41575-94-4
dc.subject.otherChemCAS carmustine, 154-93-8
dc.subject.otherChemCAS cisplatin, 15663-27-1, 26035-31-4, 96081-74-2
dc.subject.otherChemCAS cyanocobalamin, 53570-76-6, 68-19-9, 8064-09-3
dc.subject.otherChemCAS cyclophosphamide, 50-18-0
dc.subject.otherChemCAS cytarabine, 147-94-4, 69-74-9
dc.subject.otherChemCAS denileukin diftitox, 173146-27-5
dc.subject.otherChemCAS dexamethasone, 50-02-2
dc.subject.otherChemCAS doxorubicin, 23214-92-8, 25316-40-9
dc.subject.otherChemCAS etoposide, 33419-42-0
dc.subject.otherChemCAS fludarabine, 21679-14-1
dc.subject.otherChemCAS folic acid, 59-30-3, 6484-89-5
dc.subject.otherChemCAS gemcitabine, 103882-84-4
dc.subject.otherChemCAS ifosfamide, 3778-73-2
dc.subject.otherChemCAS lenalidomide, 191732-72-6
dc.subject.otherChemCAS melphalan, 148-82-3
dc.subject.otherChemCAS methylprednisolone, 6923-42-8, 83-43-2
dc.subject.otherChemCAS mogamulizumab, 1159266-37-1
dc.subject.otherChemCAS oxaliplatin, 61825-94-3
dc.subject.otherChemCAS pixantrone, 144510-96-3, 144675-97-8
dc.subject.otherChemCAS pralatrexate, 146464-95-1
dc.subject.otherChemCAS romidepsin, 128517-07-7
dc.subject.otherIndex alemtuzumab
dc.subject.otherIndex alisertib
dc.subject.otherIndex antineoplastic agent
dc.subject.otherIndex bendamustine
dc.subject.otherIndex brentuximab vedotin
dc.subject.otherIndex carboplatin
dc.subject.otherIndex carmustine
dc.subject.otherIndex cisplatin
dc.subject.otherIndex cyanocobalamin
dc.subject.otherIndex cyclophosphamide
dc.subject.otherIndex cytarabine
dc.subject.otherIndex denileukin diftitox
dc.subject.otherIndex dexamethasone
dc.subject.otherIndex doxorubicin
dc.subject.otherIndex etoposide
dc.subject.otherIndex fludarabine
dc.subject.otherIndex folic acid
dc.subject.otherIndex gemcitabine
dc.subject.otherIndex histone deacetylase inhibitor
dc.subject.otherIndex ifosfamide
dc.subject.otherIndex lenalidomide
dc.subject.otherIndex melphalan
dc.subject.otherIndex methylprednisolone
dc.subject.otherIndex mogamulizumab
dc.subject.otherIndex oxaliplatin
dc.subject.otherIndex pixantrone
dc.subject.otherIndex pralatrexate
dc.subject.otherIndex romidepsin
dc.subject.otherIndex sgn 30
dc.subject.otherIndex unindexed drug
dc.subject.otherIndex allogeneic hematopoietic stem cell transplantation
dc.subject.otherIndex article
dc.subject.otherIndex autologous hematopoietic stem cell transplantation
dc.subject.otherIndex cancer combination chemotherapy
dc.subject.otherIndex cancer prognosis
dc.subject.otherIndex cancer recurrence
dc.subject.otherIndex cutaneous T cell lymphoma
dc.subject.otherIndex cytopenia
dc.subject.otherIndex diarrhea
dc.subject.otherIndex donor lymphocyte infusion
dc.subject.otherIndex drug bioavailability
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug response
dc.subject.otherIndex fatigue
dc.subject.otherIndex graft versus host reaction
dc.subject.otherIndex graft versus lymphoma effect
dc.subject.otherIndex hematopoietic stem cell transplantation
dc.subject.otherIndex high risk patient
dc.subject.otherIndex Hodgkin disease
dc.subject.otherIndex human
dc.subject.otherIndex large cell lymphoma
dc.subject.otherIndex leukopenia
dc.subject.otherIndex lung toxicity
dc.subject.otherIndex molecularly targeted therapy
dc.subject.otherIndex mucosa inflammation
dc.subject.otherIndex multiple cycle treatment
dc.subject.otherIndex multiple myeloma
dc.subject.otherIndex myelodysplastic syndrome
dc.subject.otherIndex nausea
dc.subject.otherIndex nonhodgkin lymphoma
dc.subject.otherIndex peripheral T cell lymphoma
dc.subject.otherIndex priority journal
dc.subject.otherIndex recurrence risk
dc.subject.otherIndex salvage therapy
dc.subject.otherIndex T cell leukemia
dc.subject.otherIndex T cell lymphoma
dc.subject.otherIndex thrombocytopenia
dc.subject.otherIndex unspecified side effect
dc.subject.otherIndex Antineoplastic Agents
dc.subject.otherIndex Antineoplastic Combined Chemotherapy Protocols
dc.subject.otherIndex Hematopoietic Stem Cell Transplantation
dc.subject.otherIndex Humans
dc.subject.otherIndex Lymphoma, T-Cell
dc.subject.otherIndex Recurrence
dc.subject.otherIndex Risk Factors
dc.subject.otherKeywordPlus VERSUS-HOST-DISEASE
dc.subject.otherKeywordPlus PHASE-II TRIAL
dc.subject.otherKeywordPlus DONOR LYMPHOCYTE INFUSIONS
dc.subject.otherKeywordPlus BRENTUXIMAB VEDOTIN SGN-35
dc.subject.otherKeywordPlus LONG-TERM REMISSIONS
dc.subject.otherKeywordPlus ALLOGENEIC TRANSPLANTATION
dc.subject.otherKeywordPlus SALVAGE TREATMENT
dc.subject.otherKeywordPlus MULTIPLE-MYELOMA
dc.subject.otherKeywordPlus OPEN-LABEL
dc.subject.otherWOS Hematology

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


My Account